PIAS1 is not suitable as a urothelial carcinoma biomarker protein and pharmacological target

Holger Hans Hermann Erb, Marlies Ebert, Ronja Kuhn, Lukas Donix, Axel Haferkamp, Robert Ian Seed, Eva Jüngel

Department of Urology and Pediatric Urology, University Medical Center Mainz, Mainz, Germany, Department of Urology, Technische Universität Dresden, Dresden, Germany, National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany and Helmholtz Association/Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany, Department of Pathology, University of California, San Francisco, California, United States of America

* holger.erb@uniklinikum-dresden.de

Abstract

Urothelial cancer (UC) is one of the most common cancers in Europe and is also one of the costliest to treat. When first line therapies show initial success, around 50% of cancers relapse and proceed to metastasis. In this study we assessed the Protein inhibitor of activated signal transducers and activators of transcription (PIAS)1 as a potential therapeutic target in urothelial cancer. PIAS1 is a key regulator of STAT1 signalling and may be implicated in carcinogenesis. In contrast to other cancer types PIAS1 protein expression is not significantly different in malignant areas of UC specimens compared to non-malignant tissue. In addition, we found that down-regulation and overexpression of PIAS1 had no effect on the viability or colony forming ability of tested cell lines. Whilst other studies of PIAS1 suggest an important biological role in cancer, this study shows that PIAS1 has no influence on reducing the cytotoxic effects of Cisplatin or cell recovery after DNA damage induced by irradiation. Taken together, these in vitro data demonstrate that PIAS1 is not a promising therapeutic target in UC cancer as previously shown in different entities such as prostate cancer (PCa).

Introduction

Europe has one of the highest incidence rates of bladder cancer (BC) in the world, the majority of which are urothelial cancer (UC) [1]. Current gold-standard treatment for UC is the surgical removal of the bladder (radical cystectomy). However, ~50% patients will still relapse and proceed to develop metastasis [2]. Currently, patients with metastatic UC receive platinum-based cisplatin chemotherapy and/or radiotherapy (RT) as non-invasive therapy options either before or after cystectomy [3]. However, the success of these non-invasive therapies is still sub-optimal, and more efficient treatment protocols need to be developed.
DNA repair mechanisms play an important role in the response of cancer cells to RT or cisplatin treatment, and in the development of therapy resistance [4]. These mechanisms can remove the bulky, helix-distorting DNA adducts induced by cisplatin, as well as the DNA breaks caused by ionizing radiation [5]. Protein Inhibitor of Activated STAT (PIAS1) has been shown to play an important role in the repair of cisplatin-induced DNA cross-links and radiation-induced DNA strand breaks [6, 7]. PIAS1 belongs to the multifunctional PIAS protein family that play a role in the regulation of cytokines and other cellular pathways [8]. Besides its ability for DNA and protein binding via its conserved SAP domain, PIAS1 also contains a RING finger-like zinc binding domain (RLD) and a SUMO interaction motif (SIM), thus functioning as a SUMO-E3 ligase [8]. Therefore, PIAS1 can influence the activity of various proteins and signalling cascades. In breast and prostate cancer PIAS1 has been reported to be involved in cancer progression and appears to be a valid target for cancer therapy even in resistant cells [9–12]. However, there are currently no studies investigating either the role of PIAS1 in UC or in the development of treatment resistance.

The aim of this study is to investigate the potential role of PIAS1 in UC for the first time, and whether it may function to regulate the urothelial cell DNA damage response induced by therapeutic approaches.

Materials and methods

Data mining

For mutation analysis of PIAS1 the The Cancer Genome Atlas (TCGA, https://portal.gdc.cancer.gov/) data base was used. For PIAS1 expression analysis the dataset GSE27448, GSE3167, and GSE13507 were analysed by using GEO2R (https://www.ncbi.nlm.nih.gov/geo/ge2r/) [13–15].

Cell lines and cell culture

UROtsa, RT112, TCCSUP, T24, Cal-29 and RT4 cells were obtained from the ATCC. All cells with exception of Cal-29 were cultured in RPMI 1640 medium (Seromed, Berlin, Germany) supplemented with 10% fetal calf serum (FCS), 20 mM HEPES-buffer, 1% glutamax, and 1% penicillin/streptomycin (all: Gibco/Invitrogen; Karlsruhe, Germany). Cal-29 were cultured in Dulbecco’s Modified Eagle’s Medium (Sigma-Aldrich, Taufkirchen, Deutschland) supplemented with 10% FCS, 20 mM HEPES-buffer, 1% glutamax, and 1% penicillin/streptomycin (all: Gibco/Invitrogen; Karlsruhe, Germany).

Live cell count

Collected cells were stained with Trypan Blue (Sigma-Aldrich Chemie GmbH; Munich; Germany) and counted using a LuncaTM Second Generation Automated Cell Counter (logos Biosystems, Villeneuve d’Ascq, Frankreich).

RNA isolation and quantitative real-time PCR

Quantitative real-time PCR (qRT-PCR) experiments were performed in six-well plates. Cells were seeded in a density of 500,000 cells/well and were harvested after 48 h. RNA was isolated using the RNeasy Plus Mini Kit by following the manufacturer’s instructions (Qiagen). cDNA synthesis was performed using iScript select cDNA synthesis kit (Bio-Rad). qRT-PCR was performed using the MIC qPCR cycler (Bio Molecular Systems, Upper Coomera, Australia) and TaqMan gene expression assays for PIAS1 and HRPT1 (both Applied Biosystems). HPRT1
was used as a control. micPCR software was used for determination of Ct values. ΔCt (ΔCt = \(Ct_{GOI} - Ct_{HRPT1}\)) values were calculated and expressed as \(2^{-\Delta Ct}\).

**Irradiation of cells**

Cells were irradiated using a Gammacell 2000 (Nuklear Data, Frankfurt, Germany) at the Medical University of Mainz (Dr. Jürgen Podlech, Institute of Virology). A dose of 2.5, 5, 10, 20 or 40 Gy was administered with a dose rate of 0.044 Gy/s.

**Western blot analysis**

For western blot analysis cells were washed with Phosphate-buffered saline (PBS) and lysed in Radioimmunoprecipitation assay (RIPA) buffer with complete Mini EDTA-free protease inhibitor tablets (Roche, Welwyn Garden City, UK) and the phosphatase inhibitor cocktail PhosSTOP (Roche, Welwyn Garden City, UK). The protein quantification and western blot was performed as described earlier [16]. PIAS1 XP® Rabbit mAb (1:500, D33A7, Cell Signaling, Frankfurt am Main, Germany), Anti-β-Actin monoclonal (1:5000, AC-15, Sigma-Aldrich GmbH; Munich; Germany) and Anti-Lamin A antibody (1:1000, Abcam, Cambridge, UK) were used as primary antibody. Rabbit Anti-Mouse IgG, HRP and Goat anti-rabbit IgG, HRP (both: 1:1000, Dako, Frankfurt, Germany) were used as secondary antibody.

**Cytoplasmatic and nuclear fractionation**

Fractions were obtained using NE-PER nuclear and cytoplasmic extraction kit (Pierce, Vienna, Austria) following the manufacturer’s instructions.

**Immunofluorescence**

Cells were seeded onto glass coverslips and allowed to attach for 24 h. Depending on the assay, they were grown for 2 d without treatment (for localization studies) or transfected with siRNA against PIAS1 or control siRNA (for siRNA efficiency studies and p21 expression experiments). Subsequently, the cells were again washed with PBS and fixed with 4% paraformaldehyde for 10 min. The cells were washed with PBS and permeabilized with PBS+1% bovine serum albumin+0.2% Triton X100 for 5 min. After 30 min blocking with PBS+1% bovine serum albumin, coverslips were incubated for 1 h with primary antibodies (PIAS1 [D33A7] XP® Rabbit mAb 1:50, Cell Signaling, Frankfurt am Main, Germany). After washing with TBS + 0.1% Tween20, coverslips were incubated with the following fluorescence-labeled secondary antibodies: goat anti-rabbit 555 and donkey anti-mouse 488 (all Invitrogen). Coverslips were finally washed with TBS and mounted with Vectashield Hard Set mounting medium containing DAPI (Vector Laboratories, Burlingame, CA) on glass slides. The cells were visualized using fluorescent microscopy on an Axio Observer Z1 microscope (Carl Zeiss AG, Oberkochen, Germany).

**Transfections**

For siRNA transfections, 50 nmol/l FlexiTube GeneSolution GS8554 for PIAS1 (QIAGEN GmbH, Hilden, Deutschland) were used (PIAS1_6: SI02641975; PIAS1_7: SI02641968). The AllStars Negative Control siRNA served as control (QIAGEN GmbH, Hilden, Deutschland). Transfections of siRNA were performed with Lipofectamine RNAiMax (Invitrogen) according to the manufacturer’s protocol. For overexpression experiments, the plasmid pEGFP-C1-PIAS1wt (generated by Dr. Yaron Galanty; Gurdon Institute, Cambridge, UK) and empty vector pEGFP-C1-CTRL were used. Depending on the well size, the cells were transfected with...
1 μg/ml plasmid in 6-well plates and 0.1 μg/ml in 96-well plates using ViaFect™ Transfection Reagent transfection reagent (Promega GmbH High-Tech-Park, Mannheim, Deutschland) for 48 or 72 h following the manufacturer’s instructions.

**Measurement of cell viability**

Resazurin sodium salt (Sigma-Aldrich Chemie GmbH; Munich; Germany) was used to carry out alamar blue assays. A 25 mmol/L stock was diluted 50-fold to generate a 10-fold working stock. Cells were plated at the stated number (5×10³) per well for cell line in 96-well plates and incubated with drug. 4 h before measurement, one-tenth volume of the 10-fold working stock was added to each well and incubated for 4 h. Fluorescence (560EX nm/590EM nm) and absorbance (570 nm) was measured using a SPARK 10M Microplate reader (TECAN, Männedorf, Switzerland). Each experiment was done in triplicate. After subtracting background absorbance, results were expressed as cell growth occurring from 24 to 72 h, calculated in percentage increase from controls set to 100%.

**Clonogenic and clonogenic recovery assays**

The clonogenic potential and clonogenic recovery assays were performed and analysed as described previously [17]. 100 cells/well were given in 6-well plates. Colonies were counted after 10 d and recorded if they contained more than 32 cells (five population doublings).

**Wound heal assay**

2x10⁴ cells per well were seeded onto IncuCyte® ImageLock 96-well plates (Essense Bioscience, Hertfordshire, United Kingdom) and incubated overnight. Subsequently cells were transfection with siRNA. Experiments were seeded as four technical replicates for each condition. 24 h after transfection the IncuCyte® 96-well WoundMaker Tool (Essense Bioscience, Hertfordshire, United Kingdom) was used to make a scratch. Wound closure was observed using the IncuCyte® S3 Live-Cell Analysis System Tool (Essense Bioscience, Hertfordshire, United Kingdom). Wound closure was observed for 24 h. Pictures at 10-fold magnification were taken every 2 h. Wound closure was analysed using the Cell Migration Analysis software module (Essense Bioscience, Hertfordshire, United Kingdom).

**Drug treatment**

Cisplatin (Sigma-Aldrich Chemie GmbH; Munich; Germany) was dissolved in DMSO as a 10 mM stock solution and stored as aliquots at −20 °C. Prior to experiments, Cisplatin was diluted in cell culture medium. Cell growth experiments were carried out in the presence of 0, 2, 6, 12.5, 25 μg/ml Cisplatin for T24 and 0, 7.5, 12.5, 25 μg/ml Cisplatin for RT112. Controls remained untreated.

**Statistical analysis**

Prism 8.02 (GraphPad Software, La Jolla, CA, USA) was used for statistical analyses. Student’s t-test (two-sided), one way Anova, or two-way ANOVA were used to determine whether two sets of data were significantly different from each other. Data are presented as mean±SD or mean±SEM unless otherwise specified. P-values ≤0.05 were considered significant. All differences highlighted by asterisks were statistically significant as encoded in figure legends (⁎ P≤0.05;  ⁎⁎ P≤0.01;  ⁎⁎⁎ P≤0.001). All experiments were performed in at least three independent biological replicates.
Results

PIAS1 expression is not altered between benign and malignant urothelial tissue

To investigate PIAS1 in benign and malignant human urothelial tissue, mutation rate and expression was analysed. Mutation analysis (Fig 1A) of 2019 patients revealed a somatic mutation rate of 0.4% [18, 19]. To analyse PIAS1 expression in benign and malignant urothelial tissue, three different already published microarrays (GSE27448, GSE3167, GSE13507) were analysed [13–15]. As shown in Fig 1B, PIAS1 mRNA is expressed heterogeneously in malignant areas. However, there was no significant difference between benign and malignant human urothelial tissue (Fig 1B). PIAS1 also showed no difference in mRNA expression when muscle invasive and non-muscle invasive samples were compared (Fig 1C). Kaplan-Meier survival analysis on publically available datasets (GSE13507, GSE31684) also revealed that expression of PIAS1 had no influence on recurrence free survival (Fig 1D).

Fig 1. PIAS1 expression is not altered between benign and malignant urothelial tissue. (A) Mutation analysis of PIAS1 in benign and malignant urothelial tissue (B) mRNA expression profiles of PIAS1 in benign and malignant areas from the GSE27448, GSE3167 and GSE13507 data sets. (C) mRNA expression profiles in muscle invasive and non-muscle invasive UC from the GSE13507 data set. (D) Recurrence free survival analysis from publically available datasets (GSE13507, GSE31684) patients with low and high PIAS1 levels. The median expression level was chosen as threshold.

https://doi.org/10.1371/journal.pone.0224085.g001
PIAS1 is expressed in the nucleus of benign and malignant urothelial cell lines

PIAS1 protein expression in urothelial cell lines was determined by western blot. Antibody specificity (S1A Fig) was determined by using the PCa cell lines 22Rv1 (PIAS1 negative) and PC3 (PIAS1 positive) [20]. As shown in Fig 2A, PIAS1 protein expression could be detected in all benign and malignant cell lines. Nevertheless, PIAS1 protein expression was heterogeneous. TCCSUP showed the highest expression, whereas T-24 showed the lowest expression. Furthermore, cell fractionation (Fig 2B) and immunofluorescence (Fig 2C) methods were applied to

https://doi.org/10.1371/journal.pone.0224085.g002

Fig 2. PIAS1 is expressed in benign and malignant urothelial cell lines and shows nuclear localization. (A) Western blot analysis of PIAS1 protein levels of different bladder cancer cell lines (n = 3). PIAS1 levels were normalized on β-Actin. Data are expressed as mean±SD of three independent experiments. (B) Localization PIAS1 was determined by cytoplasmatic and nuclear fractionation in several urothelial cell lines. β-Actin was used as cytoplasmic and lamin A was used as nuclear marker. (C) PIAS1 nuclear localisation (green) in the urothelial cell lines was confirmed by immunofluorescence. Counterstaining of the nuclei was performed with DAPI staining (blue).
determine the subcellular localization of PIAS1. Both methods confirmed PIAS1 expression predominantly in the nuclei of all tested cell lines (Fig 2B and 2C).

PIAS1 does not affect cell viability or colony formation ability in urothelial cell lines

For the following experiments RT112 with an average PIAS1 expression and T24 with a low PIAS1 expression were chosen. PIAS1 is reported to play a crucial role in the proliferation of PCa cells, possibly through regulation of NFκB and STAT1, which are known regulators of cellular proliferation and apoptosis in several tumour models [10, 20–22]. To investigate the role of PIAS1 in cell viability in human urothelial cancer cell lines four siRNAs were tested. All siRNAs decreased PIAS1 mRNA expression (S1C Fig) and subsequently protein expression in RT112 cells (S1D Fig). For subsequent biological experiments siPIAS1_6 and siPIAS1_7 were chosen. In addition, overexpression of PIAS1 using the pEGFP-C1-PIAS1wt could be shown in T24 and RT112 (S1E Fig). In contrast to the findings in PCa, knock down or overexpression of PIAS1 did not influence the viability of urothelial cancer cell lines (Fig 3A and 3B). In line with this result knockdown or overexpression of PIAS1 in RT112 and T24 cells did not result in a change in number of colonies formed after 10 d in a clonogenic assay (Fig 3C and 3D).

PIAS1 knock down does not affect cell migration in urothelial cell lines

Migration plays an important role in metastasis [23]. To assess the role of PIAS1 in cell migration wound heal assays after knock down were performed. As shown in Fig 4 no change in migration could be observed after PIAS1 knockdown compared to the control siRNA in RT112 and T24 (Fig 4).

PIAS1 does not influence cell survival after cisplatin treatment

Cisplatin causes the development of DNA cross-links, e.g. 1,2-intrastrand cross-links of purine bases which result in apoptotic cell death [24]. Several studies have reported that PIAS1 may be involved in DNA cross-link repair [7, 25]. To explore if PIAS1 expression influences the effects of Cisplatin on cell viability, RT112 and T24 cell lines with overexpression or siRNA knock down of PIAS1 were treated with Cisplatin. To assess a range for Cisplatin treatment an IC50 for Cisplatin was determined in RT112 and T24 (Fig 5A). RT112 showed an IC50 of 6.5 μg/ml and T24 of 2.71 μg/ml. Therefore, a range for RT112 from 0–25 μg/ml was chosen and for T24 a range from 0–12 μg/ml. However, cell viability assays showed no change in the dose response experiments in cisplatin-treated RT112 and T24 cell lines after PIAS1 knock down (Fig 5B) or overexpression (Fig 5C) compared to controls.

PIAS1 does not influence cell survival and clonogenic recovery after irradiation

A complex network of proteins must assemble to initiate the Process of DNA damage repair (DDR) successfully. Such proteins include the RAD52 epistasis group of proteins which have been shown to be regulated by PIAS1 [26, 27]. However, it is currently unknown whether PIAS1 influences double-strand break DNA repair in urothelial cells. Therefore, RT112 and T24 cell lines with knocked down or overexpressed PIAS1 were exposed to several doses of gamma irradiation and cell viability was assessed. Neither knock down (Fig 6A) nor overexpression (Fig 6B) of PIAS1 showed any significant change in cell viability in the tested cell lines after irradiation with 2.5, 5, 10, or 20 Gy compared to the control siRNA. Clonogenic assays
Fig 3. PIAS1 down-regulation or overexpression does not change cell viability or clonogenic potential of T-24 and RT112. (A) Cell viability after PIAS1 down-regulation in T-24 and RT112 was measured by using the alamar blue assay. Data are expressed as fold changes of siCTRL and are the mean±SEM of three independent experiments. (B) Cell viability after PIAS1 overexpression in T-24 and RT112 was measured by using the alamar blue assay. Data are expressed as fold changes of siCTRL and are the mean±SEM of three independent experiments. (C) Effect of PIAS1
down-regulation on colony formation ability of T24 and RT112 cells was assessed by counting the number of colonies after 10 days. Data are expressed as mean±SEM of three independent experiments (D) Effect of PIAS1 overexpression on colony formation ability of T24 and RT112 cells was assessed by counting the number of colonies after 10 d. Data are expressed as mean±SEM of three independent experiments.

https://doi.org/10.1371/journal.pone.0224085.g003

Fig 4. Downregulation of PIAS1 does not affect cell migration in RT112 and T24 cells. Wound heal assays after PIAS1 knock down. (A) Representative pictures of wound closure at 0, 4, 8, 12, and 24 h after scratching. (B) Statistical analysis of the wound heal assays in T24 cells and RT112 cells after siRNA transfection. Data are expressed as wound width in μm and wound confluence in % and are the mean±SEM of three independent experiments.

https://doi.org/10.1371/journal.pone.0224085.g004
are commonly used to investigate survival of irradiated cancer cells, whereas cell viability assays are usually used to analyse chemosensitivity or toxicity of drugs in human tumour cell lines [28]. Therefore, clonogenic recovery assays were performed with irradiated RT112 and T24 cell lines with overexpressed or knocked down PIAS1. However, the clonogenic recovery assays showed no difference with knock down (Fig 6C) or overexpression (Fig 6D) of PIAS1 compared to the controls.
Fig 6. PIAS1 does not influence cell survival and clonogenic recovery after irradiation. (A) Dose response curves for cell viability of T24 and RT112 after simultaneous depletion of PIAS1 and irradiation (0, 2.5, 5, 10, 20 Gy) was measured by using the alamar blue assay. Data are expressed as mean±SEM of three independent experiments. (B) Dose response curves for cell viability of T24 and RT112 after simultaneous overexpression of PIAS1 and irradiation (0, 2.5, 5, 10, 20 Gy) was measured by using the alamar blue assay. Data are expressed as fold changes of untreated CTRL and are the mean±SEM of three independent experiments. (C) Clonogenic recovery assays were performed with T24 and RT112 after simultaneous depletion of PIAS1 and irradiation (0, 2.5, 5, 10, 20 Gy) and survival fractions are expressed as mean±SEM of three independent experiments. (D) Clonogenic recovery assays were performed with T24 and RT112 after simultaneous overexpression of PIAS1 and irradiation (0, 2.5, 5, 10, 20 Gy) and survival fractions are expressed as fold changes of untreated CTRL and are the mean±SEM of three independent experiments.

https://doi.org/10.1371/journal.pone.0224085.g006
Discussion

In the recent years studies have revealed an important role of SUMOylation in tumourigenesis, tumour progression, and metastasis [29]. Especially TGF-β signalling seem to be highly regulated by SUMOylation in UC [30]. Tan and colleagues revealed that SUMOylation of SnoN by the SUMO E3 ligase inhibits TGF-β induced epithelial-mesenchymal transition (EMT) and invasion [31]. In addition, the deSUMOylation protease SENP2 has shown to be involved in metastatic progression by regulating EMT and MMP13 expression in UC [32, 33]. The multifunctional E3 SUMO-protein ligase PIAS1 has been reported to play a key role in the regulation of many cellular pathways [8]. In addition to its regulatory role of STAT1 and NFκB, there is evidence that it also regulates the expression and transcriptional activity of other transcription factors such as AR [34, 35]. PIAS1 has also been shown to be involved in several important cellular processes including cell cycle control and DNA damage repair (DDR) and therefore may play an important role in genomic stability and tumourigenesis [4, 25, 27, 36].

Due to these findings it is not surprising that several groups demonstrated that PIAS1 is dysregulated and involved in tumour survival. In breast cancer, PIAS1 regulates tumourigenesis through gene silencing and may serve as a potential survival biomarker [11, 37]. In colon cancer PIAS1 has been shown to repress the cancer stem cell population. Therefore, reduced expression of PIAS1 is associated with colon cancer development [38, 39]. Several studies from Puhr et al. and Höfer et al. demonstrated a crucial role in PCa survival, AR regulation and as determinant of poor survival [9, 10, 20].

In this study, the role of PIAS1 UC was investigated for the first time. Given that sumoylation of proteins plays a critical role in the regulation of protein activity, and the TCGA database showed that PIAS1 is WT in urothelium, we hypothesized that modulation of PIAS1 might result in biological responses [25, 40]. Analysis of several public available arrays revealed that PIAS1 mRNA expression is not changed between begin and malignant tumour areas. Also, there was no difference between muscle invasive and non-muscle invasive samples. These results show that in contrast to colon cancer, breast cancer and PCa [9, 37, 39], PIAS1 might not be a potential marker for UC. Furthermore, screening of the commonly used cell lines revealed no significant differences in the expression of the PIAS1 protein in UC. However, it has been important to validate protein expression levels using primary patient specimens.

Whilst not completely clarified, data in PCa models show that upregulation of p21 by PIAS1 knock down leads to cell cycle arrest [20]. It is hypothesized that PIAS1 regulates p21 via p73 in PCa cells as it is reported to be involved in cell cycle regulation by SUMOylation of the tumour suppressors p53 or p73 [20, 41, 42]. This regulation was proven by Munarri et al., who demonstrated that PIAS1 is a check point regulator during the S phase of the cell cycle by SUMOylating p73 [42]. In contrast to these findings, knock down of PIAS1 in the tested UC cell lines showed no effect on viability or clonogenic potential. These data could be explained by the apparent lack of p73 in bladder cancer tissue and cell lines as p73 mediated cell cycle control is not present in these cells [42–44]. Due to these findings we hypothesize that PIAS1 is not involved in p21, p53 and p73 regulation in UC. However, further investigations are necessary to confirm this finding.

Cisplatin is a major frontline drug in the treatment of lung, colorectal, ovarian, head-and-neck, and UC and has been used in the clinic since 1978 [45]. It kills cancer cells by creating DNA cross-links which block cell division and result in apoptotic cell death [24]. The cisplatin-induced damage is repaired by nucleotide excision repair which has also been shown to be regulated by PIAS1 [46]. However, knock down and overexpression of PIAS1 did not influence the sensitivity to cisplatin in UC and therefore seems not to be involved in resistance to the drug.
Also, other DNA damage repair (DDR) mechanisms have been demonstrated to be regulated by PIAS1 [26, 27]. To see if there is a general impact of PIAS1 on DNA damage repair, UC cells with overexpressed and down regulated PIAS1 were exposed to several doses of gamma irradiation. Our results demonstrate that PIAS1 is also not involved in DNA repair mechanisms triggered by gamma irradiation as it has been shown in breast cancer [6]. A possible explanation may be the high levels of mutations and alterations in the DNA repair pathways and cell cycle control genes in bladder cancer [47]. These mutations may alter the normal response to DNA damage as induced here by cisplatin and irradiation and therefore not cross-talk with PIAS1.

In the present study, we have demonstrated that PIAS1 plays a minor role in cell survival and DNA repair within urothelial cancer cells in vitro. This result was surprising when compared with the results of other studies from different tumour types, and could demonstrate that PIAS1 functions differently or that PIAS1 mediated DDR is non-functional in urothelial cancers. Due to the complex nature of the PIAS1 network it is difficult to explain the lack of effects shown here, however, there is evidence that members of the PIAS family such as PIAS4 or other E3 SUMO ligases may be able to compensate the role of PIAS1 [6, 48]. There is also the possibility that interaction PIAS1 partners such as STAT1 or NFκB are not such critical survival factors in UC compared to other entities. Summed-up, the in vitro data presented here do not support the role of PIAS1 as a therapeutic target in UC cancer or as biomarker as previously shown in different entities [9, 10, 37].

Supporting information
S1 Fig. Establishment of PIAS1 knock down and overexpression. (A) Testing of the antibody specify with PIAS1 negative 22Rv1 cells and PIAS1 positive PC3 cells. (B) Visual proof of transfection efficiency in RT112 (C) Establishment of different siRNAs against PIAS1 on mRNA (D) Proof of siRNA knock down efficiency on protein level after 24 h, 48 h, and 72 h in T24 cells and RT112 cells (E) Establishment of PIAS1 overexpression in T24 cells and RT112 cells. (TIF)

Acknowledgments
The Department of Urology and Pediatric Urology, University Medical Center Mainz is acknowledged for their support and helpful discussions. This work was funded the internal research grant of the University Medical Center Mainz given to Holger Erb. The mutation analysis of PIAS1 shown here are based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.

Author Contributions
Conceptualization: Lukas Donix.
Data curation: Holger Hans Hermann Erb.
Formal analysis: Holger Hans Hermann Erb.
Funding acquisition: Holger Hans Hermann Erb.
Investigation: Holger Hans Hermann Erb, Marlies Ebert, Ronja Kuhn.
Methodology: Holger Hans Hermann Erb, Marlies Ebert, Ronja Kuhn, Lukas Donix.
Supervision: Holger Hans Hermann Erb, Axel Haferkamp, Robert Ian Seed, Eva Jüngel.
**Visualization:** Holger Hans Hermann Erb, Robert Ian Seed.

**Writing – original draft:** Holger Hans Hermann Erb.

**Writing – review & editing:** Holger Hans Hermann Erb, Robert Ian Seed.

**References**

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer. 2010; 127(12):2893–917. https://doi.org/10.1002/ijc.25516 PMID: 21351269.

2. Gakis G, Witjes JA, Comperat E, Cowan NC, De Santis M, Lebret T, et al. EAU guidelines on primary urethral carcinoma. Eur Urol. 2013; 64(5):823–30. Epub 2013/04/16. https://doi.org/10.1016/j.eururo.2013.03.044 PMID: 23582479.

3. Zhang S, Yu YH, Zhang Y, Qu W, Li J. Radiotherapy in muscle-invasive bladder cancer: the latest research progress and clinical application. American journal of cancer research. 2015; 5(2):854–68. PMID: 25973322.

4. Fojo T. Cancer, DNA repair mechanisms, and resistance to chemotherapy. Journal of the National Cancer Institute. 2001; 93(19):1434–6. https://doi.org/10.1093/jnci/93.19.1434 PMID: 11584051.

5. Sakano S, Wada T, Matsumoto H, Sugiyama S, Inoue R, Eguchi S, et al. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. British journal of cancer. 2006; 95(5):561–70. https://doi.org/10.1038/sj.bjc.6603290 PMID: 16880786.

6. Galanty Y, Belotserkovskaya R, Coates J, Polo S, Miller KM, Jackson SP. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature. 2009; 462(7275):935–9. https://doi.org/10.1038/nature08657 PMID: 20016603.

7. Ishiai M, Kimura M, Namikoshi K, Yamazoe M, Yamamoto K, Arakawa H, et al. DNA cross-link repair protein SNM1A interacts with PIAS1 in nuclear focus formation. Molecular and cellular biology. 2004; 24(24):10733–41. https://doi.org/10.1128/MCB.24.24.10733-10741.2004 PMID: 15572677.

8. Shuai K, Liu B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nature reviews Immunology. 2005; 5(8):593–605. https://doi.org/10.1038/nri1667 PMID: 16056253.

9. Puhr M, Hoefer J, Eigentler A, Dietrich D, van Leenders G, Uhl B, et al. PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer. Oncogene. 2016; 35(18):2322–32. https://doi.org/10.1038/onc.2015.292 PMID: 26257066.

10. Puhr M, Hoefer J, Neuwirt H, Eder IE, Kern J, Schafer G, et al. PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells. Oncotarget. 2014; 5(23):12043–56. https://doi.org/10.18632/oncotarget.26558 PMID: 25474038.

11. Liu B, Tahk S, Yee KM, Yang R, Yang Y, Mackie R, et al. PIAS1 regulates breast tumorigenesis through selective epigenetic gene silencing. PLoS one. 2014; 9(2):e89464. https://doi.org/10.1371/journal.pone.0089464 PMID: 24586797.

12. Dadakhujaev S, Salazar-Arcila C, Netherton SJ, Chandhoke AS, Singla AK, Jirik FR, et al. A novel role for the SUMO E3 ligase PIAS1 in cancer metastasis. Oncoscience. 2014; 1(3):229–40. https://doi.org/10.18632/oncoscience.27 PMID: 25594015.

13. Zaravinos A, Lambrou GI, Boulalas I, Delakas D, Spandidos DA. Identification of common differentially expressed genes in urinary bladder cancer. PLoS one. 2011; 6(4):e18135. https://doi.org/10.1371/journal.pone.0018135 PMID: 21483740.

14. Dyrsjkot L, Kruhoffer M, Thyljaer T, Marcussen N, Jensen JL, Moller K, et al. Gene expression in the bladder cancer: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer research. 2004; 64(11):4040–8. https://doi.org/10.1158/0008-5472.CAN-03-3620 PMID: 15173019.

15. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Molecular cancer. 2010; 9:3. https://doi.org/10.1186/1476-4598-9-3 PMID: 20597689.

16. Rane JK, Erb HH, Nappo G, Mann VM, Simms MS, Collins AT, et al. Inhibition of the glucocorticoid receptor results in an enhanced miR-99a/100-mediated radiation response in stem-like cells from human prostate cancers. Oncotarget. 2016. https://doi.org/10.18632/oncotarget.10207 PMID: 27340920.

17. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nature protocols. 2006; 1(5):2315–9. https://doi.org/10.1038/nprot.2006.339 PMID: 17406473.
18. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1. https://doi.org/10.1126/scisignal.2004088. PMID: 23550210.

19. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401–4. https://doi.org/10.1158/2159-8290.CD-12-0095. PMID: 22588877.

20. Hoefer J, Schäfer G, Klocker H, Erb HH, Mills IG, Hengst L, et al. PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. The American journal of pathology. 2012; 180(5):2097–107. https://doi.org/10.1016/j.amjpath.2012.01.026. PMID: 22449952.

21. Wang H, Yang Y, Sharma N, Tarasova NI, Timofeeva OA, Winkler-Pickett RT, et al. STAT1 activation regulates proliferation and differentiation of renal progenitors. Cellular signalling. 2010; 22(11):1717–26. https://doi.org/10.1016/j.cellsig.2010.06.012. PMID: 20624457.

22. Xia Y, Shen S, Verma IM. NF-kappaB, an active player in human cancers. Cancer immunology research. 2014; 2(9):823–30. https://doi.org/10.1158/2326-6066.CIR-14-0112.

23. Bravo-Cordero JJ, Hodgson L, Condeelis J. Directed cell invasion and migration during metastasis. Cancer immunology research. 2014; 2(9):823–30. https://doi.org/10.1158/2326-6066.CIR-14-0112.

24. Dasari S, Tchoufourou WB. Cisplatin in cancer therapy: molecular mechanisms of action. European journal of pharmacology. 2014; 740:364–78. https://doi.org/10.1016/j.ejphar.2014.07.025. PMID: 25058905.

25. Bartek J, Hodny Z. SUMO boosts the DNA damage response barrier against cancer. Cancer cell. 2010; 25(5):2097–107. https://doi.org/10.1016/j.ccr.2010.01.014. PMID: 20624457.

26. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature. 2000; 408(6811):433–9. https://doi.org/10.1038/35044005. PMID: 11100718.

27. Shima H, Suzuki H, Sun J, Kono K, Shi L, Kinomura A, et al. Activation of the SUMO modification system is required for the accumulation of RAD51 at sites of DNA damage. J Cell Sci. 2013; 126(Pt 22):5284–92. Epub 2013/09/21. https://doi.org/10.1242/jcs.133744. PMID: 24046452.

28. Buch K, Peters T, Nawroth T, Sanger M, Schmidberger H, Langguth P. Determination of cell survival after irradiation via clonogenic assay versus multiple MTT Assay—a comparative study. Radiation oncology. 2012; 7:1. https://doi.org/10.1186/1748-717X-7-1.

29. Chanda A, Sarkar A, Bonni S. The SUMO System and TGFbeta Signaling Interplay in Regulation of Epithelial-Mesenchymal Transition: Implications for Cancer Progression. Cancers (Basel). 2018; 10(9).

30. Oo HZ, Seiler R, Black PC, Daugaard M. Post-translational modifications in bladder cancer: Expanding the tumor target repertoire. Urol Oncol. 2018. Epub 2018/10/22. https://doi.org/10.1016/j.urolonc.2018.09.001. PMID: 30342880.

31. Yin X, Xu C, Zheng X, Yuan H, Liu M, Qiu Y, et al. SnoN suppresses TGF-beta-induced epithelial-mesenchymal transition and invasion of bladder cancer in a TIF1gamma-dependent manner. Oncol Rep. 2016; 36(3):1535–41. Epub 2016/07/20. https://doi.org/10.3892/or.2016.4939.

32. Tan M, Gong H, Wang J, Tao L, Xu D, Bao E, et al. SENP2 regulates MMP13 expression in a bladder cancer cell line through SUMOylation of TBL1/TBLR1. Sci Rep. 2015; 5:13996. Epub 2015/09/16. https://doi.org/10.1038/srep13996. PMID: 26369384.

33. Tan M, Zhang D, Zhang E, Xu D, Liu Z, Qiu J, et al. SENP2 regulates epithelial-mesenchymal transition of bladder cancer cells through deSUMOylation of TGF-betaRI. Mol Carcinog. 2017; 56(10):2332–41. Epub 2017/06/03. https://doi.org/10.1002/mc.22687.

34. Nishida T, Yasuda H. PIAS1 and PIASalpha function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription. The Journal of biological chemistry. 2002; 277(44):41311–7. https://doi.org/10.1074/jbc.M206741200.

35. Abe J. Multiple Functions of Protein Inhibitor of Activated STAT1 in Regulating Endothelial Cell Proliferation and Inflammation. Arteriosclerosis, thrombosis, and vascular biology. 2016; 36(9):1717–9. https://doi.org/10.1161/ATVBAHA.116.308131. PMID: 27559144.

36. Tubbs A, Nussenzwerg A. Endogenous DNA Damage as a Source of Genomic Instability in Cancer. Cell. 2017; 168(4):644–56. https://doi.org/10.1016/j.cell.2017.01.002. PMID: 28187286.

37. Chanda A, Chan A, Deng L, Kornaga EN, Enwere EK, Morris DG, et al. Identification of the SUMO E3 ligase PIA1 as a potential survival biomarker in breast cancer. PLoS one. 2017; 12(5):e0177639. https://doi.org/10.1371/journal.pone.0177639. PMID: 28493978.

38. Bogachek MV, Park JM, De Andrade JP, Lorenzen AW, Kulak MV, White JR, et al. Inhibiting the SUMO Pathway Represses the Cancer Stem Cell Population in Breast and Colorectal Carcinomas. Stem cell reports. 2016; 7(6):1140–51. https://doi.org/10.1016/j.stemcr.2016.11.001. PMID: 27916539.
39. Coppola D, Parikh V, Boulware D, Blanck G. Substantially reduced expression of PIAS1 is associated with colon cancer development. Journal of cancer research and clinical oncology. 2009; 135(9):1287–91. https://doi.org/10.1007/s00432-009-0570-z PMID: 19288270.

40. Lee JS, Choi HJ, Baek SH. Sumoylation and Its Contribution to Cancer. Adv Exp Med Biol. 2017; 963:283–98. Epub 2017/02/16. https://doi.org/10.1007/978-3-319-50044-7_17 PMID: 28197919.

41. Kahyo T, Nishida T, Yasuda H. Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Molecular cell. 2001; 8(3):713–8. https://doi.org/10.1016/s1097-2765(01)00349-5 PMID: 11583632.

42. Munarriz E, Barcaroli D, Stephanou A, Townsend PA, Maise C, Terrinoni A, et al. PIAS-1 is a checkpoint regulator which affects exit from G1 and G2 by sumoylation of p73. Molecular and cellular biology. 2004; 24(24):10593–610. https://doi.org/10.1128/MCB.24.24.10593-10610.2004 PMID: 15572666.

43. Puig P, Capodieci P, Drobnjak M, Verbel D, Prives C, Cordon-Cardo C, et al. p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. Clin Cancer Res. 2003; 9(15):5642–51. Epub 2003/12/05. PMID: 14654547.

44. Marum L. Cancer Cell Line Encyclopedia launched by Novartis and Broad Institute. Future Med Chem. 2012; 4(8):947. Epub 2012/07/26. PMID: 22826900.

45. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nature reviews Cancer. 2007; 7 (8):573–84. https://doi.org/10.1038/nrc2167 PMID: 17625587.

46. Tsuge M, Kaneoka H, Masuda Y, Ito H, Miyake K, Iijima S. Implication of SUMO E3 ligases in nucleotide excision repair. Cytotechnology. 2015; 67(4):681–7. https://doi.org/10.1007/s10616-014-9762-8 PMID: 25008297.

47. Mouw KW. DNA Repair Pathway Alterations in Bladder Cancer. Cancers (Basel). 2017; 9(4). Epub 2017/03/28. https://doi.org/10.3390/cancers9040028 PMID: 28346378.

48. Wang R, Huang S, Fu X, Huang G, Yan X, Yue Z, et al. The conserved ancient role of chordate PIAS as a multilevel repressor of the NF-kappaB pathway. Sci Rep. 2017; 7(1):17063. Epub 2017/12/08. https://doi.org/10.1038/s41598-017-16624-7